Breaking News, Trials & Filings

Altasciences Completes Phase I Study in COVID-19 Patients

Gimsilumab, a monoclonal antibody, is being evaluated in patients with or at risk of developing acute respiratory distress syndrome

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Altasciences has completed a Phase I study for gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS). Roivant Sciences has said they will prioritize gimsilumab trials in patients with COVID-19 instead of a Phase II trial in a separate disease area which had been previously planned. Clinical trials of gimsilu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters